Alicia T.
- Country
- Italy
- Department
- UOC Oncologia Medica
Research Overview
- Phase 3 Evaluation of Dostarlimab Sequential Therapy Post-Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Ficlatuzumab and Cetuximab in Recurrent or Metastatic HPV-Negative Head and Neck Squamous Cell Carcinoma
- Phase III Randomized Study of Pembrolizumab and Stereotactic Ablative Radiotherapy in Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Data & Insights
Has run more than one trial at 62 of 175 partner sites.
Specializations
Head and Neck Cancer Treatment
The investigator specializes in innovative therapeutic approaches for head and neck squamous cell carcinoma (HNSCC), with particular emphasis on recurrent and metastatic disease.
- Advanced immunotherapy combinations
- Targeted therapy with EGFR inhibitors
- Novel therapeutic combinations
Focuses on developing treatment strategies for patients with PD-L1 positive tumors and HPV-negative disease variants.
Radiotherapy Innovation
Explores advanced radiotherapy techniques and combinations for treating locally advanced head and neck cancer, particularly in older patient populations.
- Stereotactic body radiotherapy (SABR)
- Combined radio-immunotherapy approaches
- Locoregional disease control
Investigates novel therapeutic agents in combination with radiation treatment for enhanced efficacy.
Precision Oncology
Conducts research in targeted therapeutic approaches for specific head and neck cancer subtypes, focusing on oligometastatic disease and resistant tumors.
- Molecular targeted therapies
- Treatment resistance mechanisms
- Biomarker-driven therapy selection
Specializes in developing treatments for platinum-resistant cases and post-immunotherapy progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.